Citigroup Cuts Tandem Diabetes Care (NASDAQ:TNDM) Price Target to $20.00

Posted by George Bondi on Oct 3rd, 2026

Tandem Diabetes Care (NASDAQ:TNDM – Free Report) had its price target lowered by Citigroup from $24.00 to $20.00 in a research note issued to investors on Wednesday, MarketBeat.com reports. The brokerage currently has a neutral rating on the medical device company’s stock.

TNDM has been the topic of several other reports. UBS Group initiated coverage on Tandem Diabetes Care in a research report on Tuesday, July 28th. They set a “neutral” rating and a $18.00 target price on the stock. Mizuho lowered their price target on Tandem Diabetes Care from $24.00 to $20.00 and set a “neutral” rating for the company in a report on Wednesday, July 15th. William Blair started coverage on Tandem Diabetes Care in a report on Friday, August 21st. They issued an “outperform” rating for the company. Oppenheimer restated an “outperform” rating on shares of Tandem Diabetes Care in a research note on Friday, August 7th. Finally, Canaccord Genuity Group set a $40.00 price objective on shares of Tandem Diabetes Care in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $29.13.

Check Out Our Latest Stock Report on TNDM

Tandem Diabetes Care Price Performance

Shares of TNDM opened at $16.50 on Wednesday. The company has a market cap of $1.15 billion, a price-to-earnings ratio of -17.74 and a beta of 1.66. Tandem Diabetes Care has a twelve month low of $12.26 and a twelve month high of $29.65. The company has a quick ratio of 2.65, a current ratio of 3.18 and a debt-to-equity ratio of 4.62. The company has a 50 day moving average of $19.58 and a two-hundred day moving average of $18.44.

Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical device company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.01. Tandem Diabetes Care had a negative return on equity of 45.97% and a negative net margin of 6.08%.The business had revenue of $254.56 million for the quarter, compared to the consensus estimate of $254.99 million. During the same period in the prior year, the firm posted ($0.78) earnings per share. The business’s quarterly revenue was up 5.8% on a year-over-year basis. As a group, analysts predict that Tandem Diabetes Care will post -0.66 earnings per share for the current fiscal year.

Institutional Trading of Tandem Diabetes Care

Hedge funds have recently modified their holdings of the stock. First Light Asset Management LLC boosted its holdings in Tandem Diabetes Care by 157.4% during the second quarter. First Light Asset Management LLC now owns 3,383,553 shares of the medical device company’s stock worth $51,058,000 after buying an additional 2,068,838 shares in the last quarter. Engineers Gate Manager LP purchased a new stake in shares of Tandem Diabetes Care during the 2nd quarter worth about $976,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Tandem Diabetes Care during the 2nd quarter valued at about $33,000. Squarepoint Ops LLC purchased a new position in shares of Tandem Diabetes Care in the 2nd quarter valued at about $3,280,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Tandem Diabetes Care in the 2nd quarter valued at about $395,000.

About Tandem Diabetes Care

(Get Free Report)

Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company’s products are designed to work with continuous glucose monitoring (CGM) systems and digital health tools to help automate and personalize insulin therapy.

Tandem’s product portfolio includes the t:slim X2 insulin pump, which features a rechargeable design and software that supports automated insulin delivery. The company also offers the t:slim X2 pump with Control-IQ technology, an algorithm designed to adjust insulin delivery based on CGM readings, and the compact Tandem Mobi pump.